The parallel CAR19/20-modified human T cells outperformed single and tandem CAR-modified T-cells in killing leukemia cells in a mouse model, suggesting that parallel CAR19/20 is a promising therapeutic approach to preventing CD19-loss-induced relapse in B-lymphoma therapy. This evidence concerns the gene CD19 and leukemia.